Cutia Therapeutics (HKG:2487) said it completed a Phase 3 clinical trial in China for its botulinum toxin type A product for treating moderate to severe glabellar lines, according to a Monday Hong Kong bourse filing.
The study met primary and secondary endpoints, with efficacy comparable to Botox and a favorable safety profile.
The pharmaceutical company said no treatment-related serious adverse events or new safety signals were observed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.